Can one target T-cell ALL?
Authors of this article are:
A summary of the article is shown below:
Progress in our understanding of the central genes, pathways, and mechanisms in the pathobiology of T-cell acute lymphoblastic leukemia (T-ALL) has identified key drivers of the disease, opening new opportunities for therapy. Drugs targeting highly prevalent genetic alterations in NOTCH1 and CDKN2A are being explored, and multiple other targets with readily available therapeutic agents, and immunotherapies are being investigated. The molecular basis of T-ALL is reviewed here and potential targets and therapeutic targets discussed.
Check out the article’s website on Pubmed for more information:
This article is a good source of information and a good way to become familiar with topics such as:
CDKN2A;Chimeric antigen receptor;GSI;Gamma secretase inhibitor;JAK/STAT;Mutations;NOTCH1;NT5C2CAR;NUP214-ABL1;PTEN;T-ALL;T-cell acute lymphoblastic leukemia
Categories: Science News